We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
Analysis of Pfizer's first gene therapy for hemophilia B: 96% reduction in bleeding, competition with Hemgenix, and hidden risks for the market. Learn the details.
